PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer
Adding the androgen receptor pathway inhibitor apalutamide to androgen-deprivation therapy (ADT) before and after radical prostatectomy significantly improves outcomes for patients with localized high-risk prostate cancer, according to findings from the phase III PROTEUS trial presented during the Plenary Session at the 2026 ASCO Annual Meeting (Abstract LBA1).
Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows
Updated results from the phase III SENOMAC trial suggest that many patients with early-stage breast cancer and limited spread to sentinel lymph nodes can safely forgo axillary lymph node dissection (ALND), avoiding substantial long-term arm morbidity without compromising survival. The findings were presented at the 2026 ASCO Annual Meeting (Abstract LBA503).
Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC
Adjuvant treatment with the selective RET inhibitor selpercatinib significantly reduced the risk of disease recurrence, progression, or death among patients with resected stage IB to IIIA RET fusion–positive non–small cell lung cancer (NSCLC), according to results from the phase III LIBRETTO-432 trial presented at the 2026 ASCO Annual Meeting (Abstract LBA3).
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in Haiti. At the time, Dr. Hilgers emphasized that sustainability would depend on building long-term relationships with government officials and the communities being served.
Behind the Scenes of the 2026 ASCO Annual Meeting
The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues, and more.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Coming Out in the Exam Room
ASH B. ALPERT, MD, MFA Preparing for a patient I was going to see in breast oncology clinic, I noticed she was single and that her partner was female. The information system at the hospital I was working in included a patient photograph along with the usual demographic and clinical...
Metastatic Colorectal Cancer: GUCY2C-Targeted CAR T-Cell Therapy
In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated...
Prostate Cancer Screening Controversies
We read with interest the recent commentary by Derek Raghavan, MD, PhD, FACP, FASCO, FRACP, on ‘Prostate Screening Saved My Life’ Is That Really True in Most Cases?’ (The ASCO Post, April 25, 2026).1 As patient advocates, we agree with Dr. Raghavan on one important point: simplistic claims such as...
I’ve Beaten the Odds for Stage IV Lung Cancer
I learned that I had advanced stage non-small cell lung cancer (NSCLC) soon after a physician in the emergency department handed me the results of a computed tomography (CT) scan, which showed that I had lesions on my L3 and L4 vertebrae. The report stated that these lesions “were highly concerning ...
Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors
In a French phase II noncomparative trial (OCLURANDOM) reported in The Lancet Oncology, Baudin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) produced numerically better progression-free survival results than those achieved with sunitinib when used as an internal control in patients...
‘I’d Like to Agree With You…But Then We Would Both Be Wrong’
DEREK RAGHAVAN, MD, PhD, FACP, FASCO, FRACP I am pleased to respond to the Letter to the Editor from Davis and Wolinsky printed in this issue of The ASCO Post, disagreeing with my views about screening for prostate cancer.In brief, the key points of my commentary were as follows: PSA is a...
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic...
